[Clinical Characteristics and Prognostic Factors of Primary FL Patients with Grade 3 or Large B Cell Transformation].

Objective: To investigate the clinical characteristics and prognostic factors of primary follicular lymphoma (FL) patients with grade 3 or large B cell transformation, so as to provide more reference for the subsequent clinical diagnosis and treatment.

Methods: Forty-seven primary FL patients with grade 3 or large B cell transformation from March 2010 to March 2018 were selected, the clinical characteristics and survival of patients were analyzed. Cox regression model were used to evaluate the related prognostic factors.

[Effect of MiRNA-145 on Apoptosis of Leukemia HuT 78 Cells and Its Mechanism].

Objective: To investigate the effect and mechanism of miRNA-145 on leukemic cell apoptosis.

Methods: After transfection of miRNA-145 mimic and negative control mimic in leukemia cells by Lipofectamine 2000 liposome, the MTT assay was used to detect the effect of miRNA-145 on cell proliferation. Flow cytometry was used to detect the effect of miRNA-145 on cell cycle and apoptosis.

HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group.

Importance: The outcome of older patients with acute myeloid leukemia (AML) remains unsatisfactory. Recent studies have shown that HLA-mismatched microtransplant could improve outcomes in such patients.

Objective: To evaluate outcomes in different age groups among older patients with newly diagnosed AML who receive HLA-mismatched microtransplant.

[Effect of G Protein-coupled Receptor Kinase 6 on Proliferation and Apoptosis of Multiple Myeloma Cells and Its Mechanisms].

Objective: To study the effect of G protein-coupled receptor kinase 6(GRK6) on proliferation and apoptosis of multiple myeloma(MM) cells and its mechanisms.

Methods: The samples were collected from MM patients and healthy people for study in vivo. The plasma cells isolated from multiple myeloma patients, as well as U266 and NCI H929 myeloma cell lines were used for study in vitro.

[Analysis of Indicators Related with Cell Proliferation and Apoptosis in the Patients with B Cell Non-Hodgkin's Lymphoma].

Objective: To analyze the indicators related with cell proliferation and apoptosis in patients with B cell non-Hodgkin's lymphoma(B-NHL).

Methods: Seventy-two cases of B-NHL and 50 cases of reactive hyperplasia of lymph nodes were entrolled in the experimental group and control group respectively. The expression levels of proliferating cell nuclear antigen(PCNA), X-linked inhibitor of apoptosis(XIAP) and B cell lymphoma leukemia-2(BCL-2) in paraffin-embedded tissue samples of 2 groups were detected by immuno-histochemistry staining, and their ralationship with pathologic factors was analyzed.

[Infection Status and Prognosis Analysis of Epstein-Barr Virus in Patients with Newly Diagnosed Hodgkin's Lymphoma].

Objective: To investigate the Epstein Barr virus(EBV) positive rate in newly diagnosed Hodgkin's lymphoma(HL) and the prognostic significance of EBV status.

Methods: A total of 120 previously untreated patients with histologically confirmed Hodgkin's lymphoma were enrolled in this study. The EBV infection status was confirmed through examining EBV-RNA(EBER) or EBV latent membrane protein-1, and these patients were divided into EBV positive group and EBV negative group.

[Clinical Comparative Study of Two Kind Doses of Bortezomib Combinated with Bisphosphonates for Treating Patients with Multiple Myeloma Ostespathy].

Objective: To investigate the clinical efficacy and safety of conventional dose and reduction dose of bortezomib in combination with bisphosphonates for treating patients with multiple myeloma ostespathy.

Methods: A total of 150 patients with multiple myeloma ostespathy were chosen in the period from March 2011 to July 2015 and randomly were divided into 2 groups: A group (75 cases) and B group (75 cases). The patients in A and B groups were treated with conventional dose of bortezomib and reduction dose of bortezomib on the basis of bisphosphonates respectively and the clinical efficacy, the improvement rate of life quality, NRS score, levels of IL-6 and CRP before and after treatment, and the adverse effects of 2 groups were compared.

[Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].

Objective: To explore the clinical efficiency and safety of CHOP regimen containing pegylated liposomal doxorubicin (PLD) for the aged patients with advanced diffuse large B-cell lymphoma (DLBCL).

Methods: Fifty aged patients with advanced DLBCL treated in our hospital from February 2010 to February 2014 were selected and divided into two groups. Out of 50 cases, 25 cases received standard CHOP regimen (sCHOP group), other 25 cases received CHOP regimen containing PLD at dose of 30 mg/m2 (PLD+CHOP).

MicroRNA-204 inhibits cell proliferation in T-cell acute lymphoblastic leukemia by down-regulating SOX4.

Background: MicroRNAs (miRNAs) are a group of small non-coding RNAs that play important roles in the pathogenesis of human diseases by negatively regulating gene expression. The aim of this study was to explore the effect of miR-204 on cell proliferation migration and invasion in T-cell acute lymphoblastic leukaemia (T-ALL).

Method: miR-204 expression was determined in bone marrow samples from 32 leukemia patients and 32 healthy controls by quantitative real-time PCR (qRT-PCR).

MiR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma.

Background: Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation of plasma cells in the bone marrow and microRNAs play a crucial role in its tumorigenesis and development. The purpose of this study was to investigate the biological functions of miR-301a in MM.

Methods: Quantitative real-time PCR was used to detect the expression level of miR-301a.